Homburger

On February 19, 2026, Solabia Group announced that it has entered into an agreement to acquire the Mibelle Biochemistry Business from Persán, a multinational European market leader in home and personal care. The Mibelle Biochemistry Business, part of the Mibelle Group, is a Swiss innovator specializing in the development and production of high‑performance active ingredients for the cosmetics, nutraceutical and food industries. The transaction is expected to close in the first half of 2026, subject to the satisfaction of customary closing conditions. The Homburger team was led by Daniel Hasler (Corporate / M&A) and included Carlo Sulser, Cédric Berger, Anina Preusker and Viviane Egli (all Corporate / M&A), Olivier Bühlmann (Real Estate), Gregor Bühler, Joel Fink and Berem Brun (all IP / IT), Angela Casey (Employment and Executive Compensation), Reto Heuberger and Juliette Buob (both Tax) as well as Richard Stäuber and Nicolas Stocker (both Competition).   Contact Wanda Schweda / Marketing / [email protected]

On February 13, 2026, UBS Group AG successfully completed its offering of AUD 1 bn in aggregate principal amount of 7.125 per cent. Tier 1 Capital Notes. The Notes are "high trigger" regulatory capital instruments that are eligible to fulfill UBS Group AG’s Swiss going concern requirements. Upon occurrence of a "Trigger Event" or a "Viability Event", the Notes will be converted into ordinary shares of UBS Group AG in accordance with their terms. The Notes are governed by Swiss law and have been provisionally admitted to trading on the SIX Swiss Exchange. Application will be made for definitive admission to trading and listing of the Notes on the SIX Swiss Exchange. The Homburger team was led by Stefan Kramer and Benedikt Maurenbrecher (both Capital Markets) and included Lee Saladino and Olivier Baum (both Capital Markets) as well as Stefan Oesterhelt (Tax).     Contact Gloria Pünchera/ Marketing / [email protected]

On February 10, 2026, UBS Group AG successfully completed its issuance of (i) USD 2 bn in aggregate principal amount of Fixed Rate/Floating Rate Callable Senior Notes due April 2030, (ii) USD 1.5 bn in aggregate principal amount of Fixed Rate/Floating Rate Callable Senior Notes due August 2037, (iii) USD 1.25 bn in aggregate principal amount of Fixed Rate/Floating Rate Callable Senior Notes due August 2032, and (iv) USD 500 m in aggregate principal amount of Floating Rate Callable Senior Notes due April 2030 under its Senior Debt Programme. The Notes are bail-inable (TLAC) bonds that are eligible to count towards UBS Group AG's Swiss gone concern capital requirement. The Notes are governed by Swiss law, and the Notes have been provisionally admitted to trading, and application will be made for definitive admission to trading and listing of the Notes, on the SIX Swiss Exchange. Homburger advised UBS Group AG with respect to all regulatory and transactional aspects of Swiss law. The Homburger team was led by Stefan Kramer and Benedikt Maurenbrecher and included Lee Saladino and Daniel Hulmann (both Capital Markets), as well as Stefan Oesterhelt (Tax).

On 10 February 2026, Alphabet Inc., the parent company of Google LLC, successfully placed bonds in Switzerland in the aggregate amount of CHF 3.055 bn. The CHF offering was comprised of CHF 905 m aggregate principal amount of 0.4270% senior notes due 2029, CHF 700 m aggregate principal amount of 0.8900% senior notes due 2032, CHF 575 m aggregate principal amount of 1.2525% senior notes due 2036, CHF 455 m aggregate principal amount of 1.5823% senior notes due 2041, and CHF 420 m aggregate principal amount of 1.8675% senior notes due 2051. BNP PARIBAS, Paris, Lancy/Geneva Branch is acting as representative of the initial purchasers for the CHF offering, which include Deutsche Bank AG, London Branch, Goldman Sachs International, J.P. Morgan Securities plc, and Merrill Lynch International. The CHF offering is scheduled to close on or around March 3, 2026, subject to customary closing conditions. The Homburger team consists of Benjamin Leisinger and Eduard de Zordi.

Homburger is advising Transocean Ltd (NYSE: RIG), a leading international provider of offshore contract drilling services for oil and gas wells, on Swiss law matters in connection with its pending acquisition of Valaris Limited (NYSE: VAL), an industry leader in offshore drilling services across all water depths and geographies. On February 9, 2026, Transocean and Valaris announced the signing of a definitive agreement to combine the two companies under which Transocean will acquire Valaris in an all-stock transaction valued at approximately USD 5.8 bn. The enterprise value of the pro forma company is approximately USD 17 bn. The transaction brings together highly complementary, premium offshore assets. On a pro forma basis, the company will own 73 rigs able to serve customers in deepwater, harsh environment, and shallow water basins around the world. Under the terms of the all-stock transaction, Valaris shareholders will receive a fixed exchange ratio of 15.235 shares of Transocean stock for each common share of Valaris. Upon completion and on a fully diluted basis, Transocean shareholders will own approximately 53% of the combined company, with Valaris shareholders owning the remaining 47%. The transaction will be carried out by way of a court-approved scheme of arrangement under Bermuda law and is expected to close in the second half of 2026, subject to regulatory approvals and customary closing conditions, and approvals by the shareholders of each company. The Homburger team advising Transocean was led by David Oser, Micha Fankhauser and Kaiyan Yeo (all Corporate / M&A) as well as Reto Heuberger (Tax).

On February 2, 2026, OC Oerlikon announced that it has completed the divestment of its Barmag textile machinery business for manmade fibers to Rieter at an enterprise value of CHF 850 m with an earn-out of up to CHF 100 m. With the closing of this transaction, Oerlikon becomes a pure-play surface technology company, serving a broad base of customers in demanding industries – from automotive, aerospace and energy to luxury, medical, defense and semiconductors – with a toolbox of high-tech surface technologies. The Homburger team was led by Daniel Hasler (Corporate / M&A) and included Anna Peter, Nicola Togni, Matthias Müller, Alessandro Samà and Fabio Gasser (all Corporate / M&A), Dieter Grünblatt (Tax), Richard Stäuber and Nicolas Stocker (both Competition), Lorenzo Togni (Capital Markets) as well as Jürg Frick (Financing).

Homburger successfully represented U.S. artistic gymnast Jordan Chiles in proceedings before the Swiss Federal Supreme Court in connection with the 2024 Olympic Games. On January 23, 2026, the Swiss Federal Supreme Court upheld a request for revision filed on behalf of Ms. Chiles and set aside a Court of Arbitration for Sport (CAS) award that had deprived her of the Olympic bronze medal in the women’s gymnastics floor exercise final. Ms. Chiles had initially been awarded the bronze medal after her coach’s inquiry resulted in an increase to her final score. A CAS panel subsequently ruled, however, that the inquiry had been submitted four seconds after the applicable one-minute time limit and was therefore invalid. In September 2024, Homburger filed both a request for revision and an appeal with the Swiss Federal Supreme Court on behalf of Ms. Chiles. In the revision proceedings, Ms. Chiles relied on newly emerged video evidence demonstrating that the inquiry had in fact been submitted within the prescribed time limit. The Swiss Federal Supreme Court granted the request for revision, set aside the CAS award and remitted the matter to the arbitral tribunal. In doing so, it gave particular weight to the extreme time pressure to which Ms. Chiles had been subjected as a result of a gross notification error by the CAS. The belated notification left her with only hours before the issuance of the award to appoint counsel, review the case file, develop a defense strategy, draft a written submission and prepare for a hearing. «The Swiss Federal Supreme Court’s decision underscores the importance of standing firm when fairness is at stake,» the Homburger team representing Ms. Chiles said. The decision constitutes a landmark ruling in several respects, including regarding the requirements for the revision of an arbitral award under the recently revised Swiss arbitration legislation, as well as the conduct of hyper-expedited arbitration proceedings more generally. The Homburger team advising Ms. Chiles was led by Gabrielle Nater-Bass and included Stefanie Pfisterer, Richard G. Allemann and Frédéric Fitzi (all Arbitration, Litigation). Homburger acted as co-counsel together with international counsel Gibson, Dunn & Crutcher LLP.  

On January 27, 2026, SubjectWell, Inc. announced the acquisition of Swiss-based Clariness AG and the merger of Clariness and SubjectWell to form one of the largest global, full-service patient recruitment platforms, combining global scale, scientific rigor, and patient-first design to transform clinical trial access and execution worldwide. Homburger acted as transaction counsel to the selling shareholders. The Homburger team comprised Andreas Müller, Carlo Sulser, Marco Rostetter, Anina Preusker, and Viviane Egli (all M&A), Reto Heuberger and Philippe Weber (both Tax), Luca Dal Molin and Joel Fink (both IP / IT and Healthcare / Life Sciences), and Richard Stäuber, Allegra Arnold, and Timothy Porter (all Competition).

On January 15, 2026, UBS Switzerland AG successfully completed its issuance of CHF 150 m 0.435 per cent. Fixed Rate Covered Bonds due January 15, 2029, CHF 190 m 0.745 per cent. Fixed Rate Covered Bonds due January 15, 2032, and CHF 345 m 1.0225 per cent. Fixed Rate Covered Bonds due January 15, 2036, under its Covered Bond Programme. The Covered Bonds are governed by Swiss law and are listed on SIX Swiss Exchange. The Covered Bonds are indirectly backed by a portfolio of mortgages from UBS Switzerland AG’s domestic mortgage pool. The Homburger team was led by Stefan Kramer and Benedikt Maurenbrecher (both Capital Markets) and included Daniel Hulmann, Yulia Shaburnykova (all Capital Markets), as well as Stefan Oesterhelt (Tax).

On January 26, 2026, Zürcher Kantonalbank successfully completed its issuance of EUR 500 m 2.950 per cent. Fixed Rate Bonds due January 26, 2031 (the Bonds). The senior unsecured Bonds have been issued under Zürcher Kantonalbank’s Swiss base prospectus consisting of the applicable summary and securities note for the issue of bonds and short term notes of Zürcher Kantonalbank dated June 20, 2025 and the registration form for debt securities dated June 20, 2025, as updated, approved by SIX Exchange Regulation AG and final terms issued thereunder. BNP PARIBAS, Deutsche Bank Aktiengesellschaft, UBS AG London Branch, and Zürcher Kantonalbank acted as the Joint Lead Managers. Homburger acted as counsel to Zürcher Kantonalbank as issuer. The Homburger team was led by Benjamin Leisinger and included Yulia Shaburnykova (both Capital Markets). Tax aspects were covered by Dieter Grünblatt.

January 23, 2026 Homburger acted as Swiss counsel to Fastned Tico Holding I B.V., a direct subsidiary of Fastned B.V., in its capacity as borrower in connection with a Dutch law-governed EUR 100 m committed senior multicurrency term facility agreement with an additional EUR 100 m option with a European lending syndicate consisting of ABN AMRO Bank N.V., Crédit Agricole Corporate and Investment Bank, ING Bank N.V., Invest-NL Capital N.V. and Coöperatieve Rabobank U.A. Fastned B.V. is a Europe-wide operator of electric fast-charging stations and listed at Euronext Amsterdam. The Homburger team was led by Daniel Hasler (Corporate / M&A) and included Jürg Frick (Financing), Jonas Stähli and Matthias Müller (both Corporate / M&A), Stefan Oesterhelt, Reto Heuberger and Laetitia Fracheboud (all Tax) as well as Gregor Bühler (IP/IT).     Contact Wanda Schweda / Marketing / [email protected]  

On January 15, 2026, HIAG Immobilien Holding AG, a leading player in the real estate industry in Switzerland that covers the entire property value chain of portfolio/asset management, site development and transaction management, placed CHF 100 m in aggregate principal amount of 1.340 percent Green Bonds due 2033 (the Green Bonds). Raiffeisen Schweiz Genossenschaft and Basler Kantonalbank acted as Joint Lead Managers. The Green Bonds will be listed on the SIX Swiss Exchange. Homburger advised Raiffeisen Schweiz Genossenschaft in the transaction. The Homburger team was led by Benjamin Leisinger (Capital Markets) and included Yulia Shaburnykova (Capital Markets). Contact Wanda Schweda / Marketing / [email protected]  

On January 13, 2026, UBS Group AG successfully completed its issuance of EUR 1.5 bn in aggregate principal amount of Fixed Rate/Fixed Rate Callable Senior Notes due February 2031 and EUR 1.5 bn in aggregate principal amount of Fixed Rate/Fixed Rate Callable Senior Notes due January 2037 under its Senior Debt Programme. The Notes are bail-inable (TLAC) bonds that are eligible to count towards UBS Group AG’s Swiss gone concern capital requirement. The Notes are governed by Swiss law, and the Notes have been provisionally admitted to trading, and application will be made for definitive admission to trading and listing of the Notes, on the SIX Swiss Exchange. The Homburger team was led by Stefan Kramer and Benedikt Maurenbrecher (both Capital Markets) and included Lee Saladino, Olivier Baum and Daniel Hulmann (all Capital Markets) as well as Stefan Oesterhelt (Tax). Contact Wanda Schweda / Marketing / [email protected]

On January 13, 2026, Baseline Wealth Management, an established FINMA-registered portfolio manager and SEC-registered investment advisor (RIA) with offices in Geneva and Zurich, announced it has joined Creative Planning, one of the largest RIAs in the United States. The transaction represents Creative Planning’s first international acquisition and underscores the attractivity of Baseline's experience serving international and U.S. clients. The acquisition adds more than USD 1 bn in assets under management to Creative Planning. The Homburger team was led by Frank Gerhard (Corporate / M&A) and included Romain Hondius, Thomas Romelli and Constantin Khovrin (all Corporate / M&A), Alexander Wherlock (Financial Market Regulation) and Philippe Weber (Tax).   Contact Gloria Pünchera / Marketing / [email protected]  

On January 8, 2026, Santhera Pharmaceuticals Holding AG (SIX: SANN) announced that it had signed an exclusive licensing agreement with Nxera Pharma, a biopharmaceutical company listed on the Tokyo Stock Exchange, for the development, manufacturing and commercialization of AGAMREE® for the treatment of Duchenne muscular dystrophy in Japan, South Korea, Australia and New Zealand. Santhera will receive a USD 30 m cash upfront payment and a USD 10 m equity investment through the purchase of c. 530 k shares by Nxera at a 20 % premium to the 30-day VWAP. Homburger advises Santhera on the Swiss corporate, capital markets and financing aspects of the transaction. The Homburger team is led by Daniel Häusermann and includes Marco Rostetter (both Corporate / M&A, Capital Markets) and Eduard De Zordi (Financing, Investment Products, Capital Markets).

On 22 October 2025, FalconX and 21Shares announced to join forces by a merger by absorption by FalconX of 21Shares' ultimate parent company. The merger was effected in November 2025. FalconX is a leading digital assets prime brokerage providing comprehensive access to global digital asset liquidity and a full range of services to the world’s top institutions. The firm serves as a single point of access for trading, financing, custody, and direct market access (DMA) across spot, derivatives, and FX markets, supported by advanced technology and sophisticated risk management. 21Shares, through its Swiss offering vehicle 21Shares AG, offers one of the world's largest suite of cryptocurrency exchange-traded products (ETPs), making cryptocurrency investing more accessible. 21Shares will continue to operate as an independent company within the FalconX group, maintaining the same management team and brand. This acquisition strengthens the bridge between listed-market products and the crypto-native ecosystem at a time when digital assets are becoming increasingly institutionalized. Homburger AG advised 21Shares on various Swiss law- and Swiss tax-related matters in the preparation and implementation of the merger. The team was co-led by Margrit Marti (Corporate / M&A) and Benjamin Leisinger (Capital Markets / Financial Market Regulation) and included Stefan Oesterhelt, Reto Heuberger, Peter Müller, Philippe Gobet and Philippe Stiegeler (all Tax), Olivier Bühlmann and Carolina Rodriguez (both Corporate / M&A), Gregor Bühler (Data Protection and Employment), as well as Stefan Bindschedler and Simone Gloor (Financing). Contact Gloria Pünchera / Marketing / [email protected]  

On December 21, 2025, Windward Bio Group AG, a Swiss-based private, clinical-stage biotechnology company committed to improving outcomes for people living with advanced immunological diseases, announced a licensing agreement between its affiliate, LE2025 Therapeutics AG, and Qyuns Therapeutics Co., Ltd. for the development and commercialization of WIN027 (also known as QX027N), a potential best-in-disease, long-acting bispecific antibody targeting TSLP and IL-13. Under the terms of the agreement, Windward Bio will gain exclusive rights to develop, manufacture, and commercialize WIN027 outside of China, for a total of up to USD 700 m in upfront and equity consideration and development and commercial milestones, as well as tiered royalties. The Homburger team advising Windward Bio includes Andreas Müller, Margrit Marti, Timo Hasler and Lucas Forrer (all Healthcare / Life Sciences and Corporate / M&A), Stefan Oesterhelt and Juliette Buob (both Tax) and other subject matter specialists.     Contact Gloria Pünchera / Marketing / [email protected]  

On December 15, 2025, Swixx BioPharma AG announced the signing of an agreement for a strategic investment by SK Capital Partners. The investment values Swixx BioPharma at more than EUR 1.5 bn. Swixx BioPharma is a leading global full-service partner in the distribution of biopharmaceutical products operating across multiple countries in Central and Eastern Europe, Greece, Eurasia and several CIS countries, the Middle East and Latin America. Closing is expected in the second quarter of 2026, subject to customary regulatory approvals. After closing, SK Capital will become Swixx’s lead investor. Biocorp, together with the founders and other shareholders, including Mérieux Equity Partners and HBM Healthcare Investments, will reinvest alongside SK Capital. Homburger is acting as counsel to Biocorp, the founders of Laboratorios Biopas, which was acquired by Swixx BioPharma in summer 2024 and, as part of that transaction, became shareholders in Swixx BioPharma. The Homburger team includes Andreas Müller, Claude Lambert, Hans Glent Abildgaard (all Corporate / M&A) and other subject matter specialists.  

On December 12, 2025, Aris Mining Corporation (TSX: ARIS; NYSEA: ARMN) announced the completion of its acquisition of the remaining 49% interest in the Soto Norte joint venture in Colombia from MDC Industry Holding Company LLC (Mubadala). Aris Mining Corporation now owns 100% of the Soto Norte project, a high-grade, long-life underground gold project that incorporates industry-leading environmental and social design features. The Homburger team was led by Daniel Hasler (Corporate / M&A) and included Marco Rostetter (Corporate / M&A) as well as Jürg Frick (Financing).

On December 8, 2025, EQT announced the sale of an additional 10% stake in Galderma Group AG (SIX: GALD) by a consortium led by EQT, which includes Sunshine SwissCo GmbH (SSCO), Abu Dhabi Investment Authority (ADIA) and Auba Investment Pte. Ltd. (all acting as sellers) to L’Oréal S.A. for an undisclosed amount. Following the transaction, which is subject to customary regulatory approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The EQT-led consortium and L’Oréal agreed to customary provisions for an investment of this type. The previously concluded shareholder undertaking between SSCO and L’Oréal will be dissolved effective upon completion of the transaction. In connection with the increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal. Homburger acted as transaction counsel to EQT. The team was led by Frank Gerhard and Margrit Marti, and comprised Carlo Sulser, Estelle Piccard, Jannis Zafeirakos and Viviane Egli (all Corporate / M&A, Capital Markets), Stefan Oesterhelt and Laetitia Fracheboud (both Tax), Richard Stäuber and Giulia Meier (both Competition) as well as Micha Fankhauser (Financial Market Regulation).